JACKSONVILLE, Fla., March 08, 2017 -- ParkerVision, Inc. (Nasdaq:PRKR), a developer and marketer of semiconductor technology solutions for wireless applications, today announced that the Patent Trial and Appeal Board (“PTAB”) has issued its latest decisions with regard to the petitions for Inter Partes Review (“IPR”) filed by Qualcomm against ParkerVision patents, increasing the favorable decisions to over six out of the ten petitions originally filed.
ParkerVision received early favorable rulings in March 2016 when the PTAB rejected Qualcomm’s request for institution on three IPR challenges to a ParkerVision patent. With these most recent PTAB decisions, ParkerVision has received three additional favorable decisions and one split decision, confirming the validity of claims from a second challenged patent. Qualcomm received favorable rulings on two IPR’s and ParkerVision chose early on not to defend one IPR challenge.
With these latest decisions, there are no further IPR’s challenging ParkerVision patents currently before the PTAB.
ParkerVision CEO Jeffrey Parker commented, “We continue to take positive steps forward in our Qualcomm proceedings and believe these results are indicative of the strength of ParkerVision’s innovations and our plan to realize the value of those assets, particularly in light of the high success rate of petitioners in invalidating patents through IPR challenges. We are pleased that the PTAB confirmed the validity of claims from both of the patents we chose to defend.”
About ParkerVision
ParkerVision, Inc. designs, develops and markets its proprietary radio-frequency (RF) technologies that enable advanced wireless solutions for current and next generation communications networks. Protected by a highly-regarded, worldwide patent portfolio, the Company’s solutions for wireless transfer of RF waveforms address the needs of a broad range of wirelessly connected devices for high levels of RF performance coupled with best-in-class power consumption. For more information please visit www.parkervision.com. (PRKR-G).
Safe Harbor Statement
This press release contains forward-looking information. Readers are cautioned not to place undue reliance on any such forward-looking statements, each of which speaks only as of the date made. Such statements are subject to certain risks and uncertainties which are disclosed in the Company's SEC reports, including the Form 10-K for the year ended December 31, 2015 and the Forms 10-Q for the quarters ended March 31, June 30, and September 30, 2016. These risks and uncertainties could cause actual results to differ materially from those currently anticipated or projected.
CONTACT: Cindy Poehlman Chief Financial Officer ParkerVision, Inc. 904-732-6100, [email protected] or Matt Steinberg The Piacente Group 212-481-2050, [email protected]


Lloyds Banking Group to Close Invoice Factoring Business by End of 2025
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 



